Please login to the form below

Not currently logged in
Email:
Password:

AstraZeneca takes $50m hit to drop Targacept’s antidepressant

Deal to develop TC-5214 is terminated after phase III trials fail to prove drug's efficacy

AstraZeneca has pulled out of a research collaboration with Targacept to develop its investigational antidepressant TC-5214 after the drug failed to live up to expectations in late-stage trials.

AZ will pay impairment charges of $50m to exit the deal for TC-5214, which was being developed as an adjunct treatment for patients with major depressive disorder (MDD), and all regulatory plans for the product have been halted.

The pharma firm dropped the drug after two phase III studies failed to reach their primary endpoint of change of a patient's score on the Montgomery-Asberg Depression Rating Scale (MADRS) after eight weeks of adjunct treatment compared to placebo.

The decision brings an end to the collaboration AstraZeneca and Targacept struck in 2009 when the Anglo-Swedish pharma firm acquired rights to the drug for an upfront payment of $200m, with over a $1bn available to Targacept in additional payments.

Despite initial high hopes for the drug, which is designed to calm neuronal nicotine receptors (NNRs) in the brain, its development has failed to match expectations.

Data released in November from previous phase III trials also demonstrated a lack of efficacy in the drug, although at the time AstraZeneca said it was committed to filing the drug for approval as a treatment for patients who have an inadequate response to a selective serotonin reuptake inhibitor (SSRI) or serotonin/norepinephrine reuptake inhibitor (SNRI).

AZ's latest announcement comes one year after GlaxoSmithKline (GSK) ended its research partnership with US biopharmaceutical company Targacept.

The GSK collaboration, which aimed to develop medicines in a variety of therapy areas that targeted NNRs, was terminated due to “significant strategic changes in the neurosciences area”, according to GSK.

That deal was worth up to $1.5bn for Targacept if milestones were met in developing products for pain, smoking cessation, addiction, obesity and Parkinson's disease.

20th March 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Medical Communications

dna: as different as you. Every patient, disease and therapy is di­fferent. As is every message, stakeholder and educational challenge....

Latest intelligence

If you needed an organ transplant, would you have one?
Lauren Packer discusses the worsening problem in the UK with an imbalance between the number of organs needed, and the number of those being donated....
Why tugging at our heartstrings is no longer enough to make us open our purses
Charlotte Shyllon (Director and Partner) and Maren Thurow (Senior Account Executive), discuss the highly emotive Make a Child Cry campaign video from Doctors of the World (Médecins du Monde)....
quantify_messages.png
Exploring full potential of e-detailing data
Today’s high quality e-detailing data can create better quality conversations with healthcare professionals and result in improved access and relationships....

Infographics